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dverse events following immunisation
ntensive monitoring
a b s t r a c t
Background: When adjuvant vaccines against the pandemic inﬂuenza A (H1N1) virus became available
after an accelerated registration process, safety issues dominated the public debate. As part of the immu-
nisation campaign, the Dutch government installed an active monitoring of possible adverse events
following immunisation (AEFIs). As part of the monitoring we conducted an anonymous prospective
cohort study to identify and quantify the occurrence of AEFIs related to pandemic vaccination among the
population immunised in general practice.
Method: Adults aged 60 years and older or personswith a risk-elevatingmedical condition recommended
for vaccination in general practice were eligible for participation. After receipt of the ﬁrst pandemic
vaccine the administrator handed over an information ﬂyer of the web-based monitoring program. The
patient could sign up for study participation online.Within oneweek, threeweeks and threemonths after
the ﬁrst immunisation questions were asked about demographics and health, immunisations, injections
site reactions and labeled reactions as well as other possible new AEFIs.
Results: In all, 3569 participants ﬁlled in the ﬁrst questionnaire. Corresponding ﬁgures for the second
and third questionnaires were 3395 (95.1%) and 3162 (88.6%). Mean age was 58 years (SD 15) and 50.1%
was female. Main indication was 60 years or older followed by presence of pulmonary or cardiovascular
disease. Of all participants, 1311 (37%) reported an AEFI. Unexpected serious reactions were not reported
nor were there signals of possible new AEFIs. The occurrence of an AEFI was determined by gender, age
and type of co-morbidity.
Conclusion: The web-based intensive monitoring system among patients immunised in general practice
revealed AEFIs due to pandemic vaccination in one-third of participants. There were no unexpected seri-
ous adverse events in this population. This advanced methodology can be further developed to monitor
f vaccreal-time use and AEFIs o
. Introduction
InMarch and early April 2009,Mexico experienced outbreaks of
espiratory illness and increased reports of patientswith inﬂuenza-
ike illness. On April 23 several cases of severe respiratory illness
ere conﬁrmed as swine origin inﬂuenza A (H1N1) [1]. The virus
pread throughout the world and on June 11, 2009, the World
ealth Organization declared an inﬂuenza pandemic [2].
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Vaccination is the most effective measure to control the spread
of inﬂuenza virus and reduces associated morbidity and mortal-
ity. The development of vaccines against the inﬂuenza A (H1N1)
virus becameahighpriority for vaccinemanufacturers. In the Euro-
pean Union special registration procedures were put in place in
order to speed up the availability of vaccines. These procedures
managed by the European Medicines Agency allowed an inﬂuenza
vaccine to be authorised more quickly than the 18–24 months usu-
ally required [3]. By the end of September and beginning of October
2009, three inﬂuenza vaccines were approved for marketing in
the European Union, Focetria®, Pandemrix® and Celvapan® [3].
When the vaccines became available a ﬁerce public debate about
their safety started in the Netherlands as well as in the rest of the
world. Because the new inﬂuenza vaccines only had been tested
in a small population and had been approved through an accel-
erated registration process, the public was concerned about the
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sFig. 1. Response rate of
accine actually causing inﬂuenza, Guillain-Barré syndrome and
ther neurological syndromes and adjuvants being harmful [4]. As
art of the large-scale immunisation campaigns carefulmonitoring
f theadverseevents following immunisation (AEFIs)was therefore
rgently needed [5,6]. An adverse event following immunization is
eﬁned by the WHO as a medical incident that takes place after an
mmunization, causes concern and is believed to be caused by the
mmunization [7].
The Netherlands Pharmacovigilance Centre Lareb was
ppointed by the Dutch Ministry of Health to monitor the safety of
he pandemic vaccines. In addition to the spontaneous reporting
ystem, Lareb was asked to conduct a prospective cohort study
sing a modiﬁed form of the intensive monitoring methodology to
ollow people who had been vaccinated with Focetria® in general
ractice during a three month period [8–10].The aim of this study
as to identify and quantify AEFIs associated with the pandemic
accine Focetria®. Secondly, we investigated risk factors for the
ccurrence of AEFIs.
. Method
.1. Setting and study population
In the Netherlands, the Health Council, which acts as an advisor
o the Minister of Health, recommended vaccination to all persons
ith a medical indication which warrants the seasonal ﬂu vaccina-
ion (persons with pulmonary-, cardiovascular- and renal disease,
iabetes and immunodeﬁciency), healthy persons above the age of
0, pregnant women in the 2nd or 3rd trimester, health care per-
onnel with direct patient contact and family members and care
iversofpatientswithahigh riskof serious complications following
n inﬂuenza infection were offered the vaccine [11,12] The vacci-
ation of all the above mentioned groups except the health care
ersonnelwould be carried out by the general practitioner. Speciﬁc
oftware to search for these patients in general practice has beenifferent questionnaires.
in use since 1995 and has been updated according to the guidelines
[13].
GPs who had reported an ADR to Lareb in the past two years
and all GPs living in the Northern provinces of the Netherlands
(duplicate addresses were identiﬁed), in total 989 practices, were
sent an invitation letter with information about the study. Of those
practices 117 responded that they wanted to participate in the
study. 100,000 ﬂyers were sent to these practices to hand out to
the patients during their ﬁrst pandemic vaccination in November
2009. The ﬂyer contained information about the aim of the study
and instruction on how to sign up for the study via a dedicated and
password safeguarded website. Eligible participants were those
who were enlisted at the general practice who met the eligibility
criteria for such immunisation according to the guidelines of the
Dutch Health Council as described above.
2.2. Data collection
Data were collected between November 16, 2009 and March
3, 2010. After online registration, patients received a question-
naire via e-mail within a week after the ﬁrst immunisation. In the
vaccination schedule an interval of at least two weeks was recom-
mended between the ﬁrst and second immunisation. The second
questionnaire in which AEFIs attributed to the second immunisa-
tionwere reported,were sent threeweeks later. The thirdquestion-
nairewas sent threemonths after theﬁrst questionnaire tomonitor
AEFIs with a late onset. If the participant failed to ﬁll out one
questionnaire, a reminder was sent after 7 days. Non-responders
were considered to be lost to follow up and did not receive any
further questionnaires (see participant ﬂow, Figs. 1 and 2). In the
questionnaires, questions were asked about personal characteris-
tics that could be potential risk factors for developing AEFIs, the
received vaccinations and possible AEFIs (see Appendix A). In order
to increase the response rate andmake thequestionnairemoreuser
friendly, we actively asked for injections site reactions and labeled









































uig. 2. Indication for vaccination. Age is the main indication followed by pulmonar
ercentages add up to more than 100%.
eactions such as fatigue, inﬂuenza-like illness, headache, myal-
ia, arthralgia, pyrexia and enlarged lymph nodes throughmultiple
hoice questions [14]. Other possible AEFIs could be ﬁlled in as free
ext. If the patient reported an AEFI which was considered to be
erious according to the Council for International Organizations of
edical Sciences, CIOMS, criteria, the seriousness of the event was
rst assessed by two assessors. If deemed serious, the report was
xported to the Lareb database and handled according to the Euro-
ean regulations for serious adverse drug reaction reports [15,16].
uestionnaires were designed and data were collected using the
ommercially available software Survey Monkey with secure entry
17]. Before ﬁnalising and sending the questionnaire, it was tested
y a test panel for comprehensibility.
.3. Sample size and data analysis
Since no datawere available on the occurrence of AEFIs, we con-
ervatively assumed a prevalence of potential AEFIs after one week
f 10% based on data from seasonal inﬂuenza vaccines. The sample
ize calculation was done for the risk factor analysis. According to
he rule of thumb to have adequate statistical power to develop
multivariable model with at least 10 cases for each determinant,
e needed at least 2000 participants.Weused descriptive statistics
o describe response rate, gender, age, indication for vaccination,
dministration of seasonal vaccination, injection site reactions and
abeled reactions. The latency, outcome and duration of the AEFIs
ere analysed as well as action taken when experiencing an AEFI,
f the patient had experienced the reaction in association with the
easonal inﬂuenza vaccine in the past and other reasons for the
EFI. AEFIs reported as free text were coded by a qualiﬁed assessor
sing the theMedicalDictionary forRegulatoryActivities,MedDRA,
ower Level Term, LLT [18]. Reactions were grouped per Med-
RA Preferred Term, PT. The reported reactions were divided into
abeled and not labeled according to the EPAR. Reactions that were
ot labeled and considered to be potential signals were analysed
n a case by case basis. In the case by case analysis causality was
ssessed by looking at the temporal relationship between the drug
nd the reaction and to exclude other causes for the reaction.Multivariable logistic regression was carried out to develop a
rediction model of risk factors for developing an AEFI encoded
s a dichotomous outcome variable (yes/no). Potential risk factors
ere age (in four equally sized categories, the youngest group was
sed as reference category), gender and thedifferent indications forcardiovascular disease. Since the patient could choose one or more indications the
the vaccination (dichotomous). Both backward and forward selec-
tion procedures were used with a signiﬁcance level of <0.05 to
develop the model. Odds ratio’s and their 95% conﬁdence inter-
val (95% CI) were estimated as measures of relative risks. The
Hosmer–Lemeshow goodness of ﬁt was assessed as a measure of
calibration of the ﬁnal model. Data were analysed using SPSS 17 for
Windows.
3. Results
In total, 3775 persons registered as potential participants (see
Fig. 1). Of these persons, 3569 (94.5%) ﬁlled in the ﬁrst ques-
tionnaire. Mean age of the respondents was 58.4 years (standard
deviation (SD) 14.8 years) and 1789 (50.1%) were female. The main
indication for use was age above 6o, followed by pulmonary- and
cardiovascular disease (Fig. 2). Of the respondents 85.1% reported
to have received the second immunisation. The majority had also
received the seasonal ﬂu vaccination a few weeks earlier (84%).
In total 1311 (37%) of the participants reported an AEFI. After
the ﬁrst vaccination, 963 (27%) participants reported to have expe-
rienced 2401 AEFIs. After the second immunisation 746 (24.6%)
patients reported 2479 AEFIs. 420 patients reported an AEFI after
both the ﬁrst and the second immunisation. 43 patients reported
69 AEFIs, which were not possible to attribute with certainty to nor
the ﬁrst nor the second immunisation.
There were no differences in loss to follow up between the
ﬁrst and second questionnaire between patients who had reported
an AEFI and patient who did not report AEFIs (chi-squared test,
p=0.52).
3.1. Injection site reactions
After the ﬁrst immunisation, 562 patients reported 1065
injection site reactions (1.9events/patient). After the second immu-
nisation 472 patients reported 1240 injection site reactions (2.6
events/patient). See Table 1 for an overview of the type of reac-
tions. Table 3 provides additional information about the injection
site reactions.3.2. Labeled AEFIs
494 patients experienced 1077 labeled AEFIs (2.2
events/patient) after the ﬁrst immunisation. After the second
1944 L. Härmark et al. / Vaccine 29 (2011) 1941–1947
Table 1
Injections site reactions reported after the ﬁrst and second immunization. In total
562 patients reported an injection site reaction after the ﬁrst immunization and
472 patient reported such a reaction after the second immunization. The patients
could report one or more injection site reactions, therefore the total number of
reactions per immunization exceeds the number of patients reporting an injection
site reaction. The percentages are calculated using the total number of respondents





Injection site pain 445 12.5
Injection site swelling 231 6.5
Injection site erythema 153 4.3
Injection site warmth 122 3.4
Injection site bruising 61 1.7
Injection site itching 53 1.5
2nd immunisation
Injection site pain 469 13.9
Injection site swelling 289 8.5
Injection site erythema 187 5.5
Injection site warmth 129 3.8
Injection site bruising 87 2.6
Injection site itching 79 2.3
Table 2
Labeled AEFIs reported after the ﬁrst and second immunization. In total 494 patients
reported a labeled AEFI after the ﬁrst immunization and 472 patient reported such
a reaction after the second immunization. The patients could report one or more
labeled AEFIs, therefore the total number of reactions per immunization exceeds
the number of patients reporting an injection site reaction. The percentages are cal-



































Information about injections site reactions grouped per immunisation. The time to
onset is given as a latency and the duration of the reaction is described as well.
Injection site reactions 1st immunisation 2nd immunisation
Time to onset Less than 1 day Less than 1 day
Duration of AEFI 3 days 3 days
Contact general practitioner 2.3% 2.8%
Treatment 0.2% 0.0%
Recovering/resolving 95.6% 95.6%





Information about frequently occurring AEFIs grouped per immunization.
Frequently occurring AEFIs 1st immunisation 2nd immunisation
Latency 1 day 1 day
Duration 2 days 3 days
Contact general practitioner 11.5% 15.8%
Treatment 3.5% 4.5%
froma sample of 72 general practices, believed to be representativeArthralgia 107 3.2
Pyrexia 88 2.6
Lymph nodes enlarged 30 0.9
mmunisation 1121 labeled AEFIs were reported by 389 patients
2.9 events/patient). See Table 2 for an overview of the type of
eactions. Table 4 provides additional information about the fre-
uently occurring AEFIs. Because some of the frequently occurring
EFIs are similar to inﬂuenza symptoms, the question was asked if
here were any other factors contributing to the occurrence of the
eaction. Nasopharyngitis was the most commonly reported other
actor followed by inﬂuenza, increased infections susceptibility,
atigue and stress.
.3. Other AEFIs
190 patients reported 264 other AEFI after the ﬁrst immu-
isation (1.4 events/patient). After the second immunisation 83
atients reported 118 AEFIs (1.4 events/patient). In the third ques-
ionnaire which was ﬁlled in after three months 43 patients
eported 69 AEFIs (1.6 events/person). For an overview of reported
eactions see Table 5. None of the reported AEFIs were considered
o be potential signals. In total 3 reports (incidence of 1/1000) were
eceived concerning serious AEFIs leading to one of the CIOMS cri-Recovering/resolving 83.6% 8480.0%




teria. The reactions reported were atrial ﬁbrillation, aggravation of
MS and inﬂuenza-like illness persisting for over a month.
3.4. Logistic regression
Malepatients experienced lessAEFIs than females and the riskof
AEFIs decreases with age (see Table 6). Cardiovascular disease, pul-
monary disease, immunodeﬁciency and pregnancy increased the
risk of an AEFI.
4. Discussion
4.1. Principal ﬁndings
Prior to the large-scale immunisation campaign against the
inﬂuenza A (H1N1) virus a ﬁerce public debate about the safety of
adjuvanted pandemic vaccines. Our study shows that the incidence
ofAEFIs in thepopulationwhowere vaccinatedby thegeneral prac-
titioners in the Netherlands was 36.7%. The results of the current
study do not raise any concerns about the safety of the used vac-
cine in The Netherlands. The reactions reported were expected and
non-serious. Injection site reactions and labeled AEFIs have a short
latency, a short duration and are in most cases self-limited. The
occurrence of an AEFI was determined by gender, age and type of
co-morbidity.
4.2. Strengths and weaknesses
Since we did not control how many of the 100,000 ﬂyers were
actually handed out at the GPs ofﬁce we do not know if there is
a selection bias in who was given a ﬂyer for participation or not.
Because the lack of denominator data it is also not possible to
calculate an over all response rate (numbers of patients partici-
pating/number of patients receiving a folder).
In order to check if the population of this cohort was represen-
tative for the patients receiving the pandemic inﬂuenza vaccine in
general practice, the population was compared to vaccination datafor theDutchpopulationasdescribed in the report ‘MonitoringVac-
cination rate, Dutch National Inﬂuenza Prevention Program 2009’.
When comparing the characteristics between these two cohorts
the percentage of men is slightly higher in our cohort (49.9% com-
L. Härmark et al. / Vaccine 2
Table 5
AEFIs reported as free text grouped per Meddra PT and per immunisation. For each























































Pain in extremity 4
ared to 49.6%). The main indication for vaccination in this cohort
hich is assumed to be representative for the Dutch population
as, except age, cardiovascular disease, followed by pulmonary
isease and diabetes mellitus. This is similar with the indications
n our cohort [19].
Only patients with a medical indication which warrants the
easonal ﬂu vaccination, healthy persons above the age of 60, preg-
ant women in the 2nd or 3rd trimester, and family members
nd care givers of patients with a high risk of serious complica-
ions following an inﬂuenza infection were vaccinated in general
ractice. How these results apply to children and healthy adults is
ncertain, notably since young age seems to be associated with
ore AEFIs. In The Netherlands, children were vaccinated with
able 6
ogistic prediction model for the occurrence of an AEFI.
OR p
Gender 0.6 (0.50–0.70) <0.001
Age (0–52.5 years)
Age (52.5–61.9 years) 0.54 (0.44–0.67) <0.001
Age (61.9–67.2 years) 0.4 (0.32–0.50) <0.001
Age (67.2–90.0 years) 0.3 (0.23–0.38) <0.001
Cardiovascular disease 1.32 (1.08–1.62) 0.008
Pulmonary disease 1.36 (1.13–1.65) 0.001
Immunodeﬁciency 1.5 (1.15–1.95) 0.003
Pregnancy 2.61 (1.55–4.40) <0.001
osmer and Lemeshow test chi-square 4.593, df 7, p=0.709.9 (2011) 1941–1947 1945
another adjuvanted vaccine (Pandemrix®), so comparisons are
difﬁcult.
Injection site reactions and labelled reactions were actively
asked for, other reactions could be reported as free text. Because
it might be easier for a patient to answer a question with a multiple
choice option than ﬁlling in AEFIs as free text, there might be an
overestimation of the AEFIs where multiple choice questions were
used.
For injection site reactions the causality is strong since there is
a very clear link between the injection and the reaction. For the
labeled AEFIs and the reactions that were reported as free text, it is
more difﬁcult to assess causality, most of the symptoms can also be
due to inﬂuenza itself. In order to see to what extent patients were
aware of other factors playing a role in the occurrence of the AEFI,
patients were asked to name other factors. Nasopharyngitis was
the most commonly reported other factor followed by inﬂuenza,
increased infections susceptibility, fatigue and stress. These factors
were only reported by a small proportion of all patients reporting
a labeled AEFI.
In this study it was assumed that all reactions reported in the
ﬁrst questionnaire were attributed to the ﬁrst vaccination an all
reactions in questionnaire two, plus the injection site reactions
and frequently occurring AEFIs in the third questionnaire were
attributed to the second vaccination if the second vaccination had
been taken. Since this division between the ﬁrst and second immu-
nisation is done after collecting the data, there is a possibility that
reactions, which were considered to be attributed to the second
vaccination actually were caused by the ﬁrst vaccination.
In recent years the patient has become an important player
in pharmacovigilance and in a number of countries patients are
allowed to submit reports to a spontaneous reporting system [20].
Patients do not have a professional ﬁlter in what to report; there-
fore the chance of ﬁnding new associations is high. A disadvantage
often mentioned with patient reports is that they are not medically
conﬁrmed. For the type of reactions reported in this study, medi-
cal conformation is not necessary. In the cases where AEFIs were
reported which were considered to be serious, follow up informa-
tion was asked in order to conﬁrm the diagnosis.
This study was performed using web-based questionnaires.
With web based questionnaires, it is possible to structure the data
received so that they will be more complete than data received
on paper. Through the web based character of the study, interim
analysis could be performed at any time, making it possible to
monitor the AEFIs in real time. Older people might be underrepre-
sented in the cohort since they are not familiar with using internet.
Recent statistics show that 86% of Dutch households have access to
internet, however persons aged above 75 and persons living in an
institution were not included [21].In this study the patient was followed over time making it pos-
sible to collect information about latency, recovery and duration of
the AEFI. This type of information is important, since it can reas-
sure the patient who will be immunized. This type of information
AEFI+ AEFI−




































































any conﬂict of interest.
Appendix A.
Questions asked in the questionnaires.
1. Gender
2. Date of birth
3. On which date did you receive your Inﬂuenza A H1N1 immunisation?
4. Is this your ﬁrst or second immunisation?
1st
2nd
5. Did you receive the seasonal ﬂu immunisation earlier this year?
Yes
No









I work in health care
Do not know/unknown
Other reasons than above mentioned
7. Did you experience any AEFIs from the inﬂuenza A H1N1 vaccine?
Yes
No
If No, end of questionnaire
8. If Yes, did it concern an injection site reaction?
Yes
No
If No, skip to question 18







10. Since when do you have this reaction?






No, none of the above
12. If one of the above situations occurred, do you give us permission to contact
you for further information?
Yes
No
13. Have you recovered from the AEFI?
Yes, I have
The AEFI is getting less severe but I am not fully recovered yet946 L. Härmark et al. / Va
s rarely presented in the SmPC and spontaneous reporting might
ot be able to capture it, therefore web-based cohort monitoring
an be a valuable addition.
.3. Strengths and weaknesses in relation to other studies
The SmPC of Focetria reports a study conducted with 131 adults
nd 123 elderly. In this study most of the AEFIs were mild and of
hort duration. The incidence of symptoms observed in subjects
ver 60 years of age was generally lower as compared to subjects
ged18–60years [14]. In a studydonebyClark et al. thevaccinewas
ested in 176 adults 18–50 years of age. 80% of subjects reported
dverse reactions after either dose (73% after the ﬁrst and 60% after
he second). The frequencyor severitydidnot increase after the sec-
nd dose was administered. The reported reactions were graded as
ild or moderate and were generally self limiting resolving within
72h period. The most frequent local and systemic reactions were
ain at the injection site and muscle aches [22]. The incidence of
EFIs in these studies ismuch higher compared to the incidences in
ur study. A possible explanation might be that the data collection
ethods differs between our study and this study. In this study self
ompleted diaries where used where patients could report both
olicited an unsolicited symptoms. The study by Clarke et al. was
erformed in a group aged 18–50 years, in our study the median
ge was 58 years. It has also been clear both from clinical trials as
ell through the logistic regression in this study, that young age is
ssociated with more AEFIs than older age, this might be another
xplanation for the higher incidence rate.
Also for the labeled AEFIs the incidencies in the SmPC for
eadache, myalgia and fatigue are higher than in our cohort
hereas the incidence of arthralgia and pyrexia are consistentwith
ut ﬁndings. The incidence of inﬂuenza like illness is much higher
n our cohort than mentioned in the SmPC. A possible explanation
or this is that the patients in our cohortwere vaccinated during the
nﬂuenza season and it is possible that the symptoms they report
re actually due to inﬂuenza itself instead of the vaccine.
Both clinical trials as our study are prospective cohort stud-
es. The difference between them is that with our study we did
ot have any additional inclusion or exclusion criteria, making it
ossible to collect data from the actual users of the vaccine. Fur-
hermore because of its observational character it is possible to
ollow a greater number of patients as compared to clinical trials
hich makes it possible to gather more data. Because we worked
ith three questionnaires it was also possible to follow the time
ourse of the AEFIs and report information about time to onset,
uration of AEFI and action taken when experiencing an AEFI, data
hich are rarely published as a result of RCT whose main focus is
o investigate efﬁcacy and not report on AEFIs.
.4. Meaning of the study and future research
This study showtheADRspectrum in thepopulation immunised
n general practice in the Netherlands. In order to get a complete
icture of the AEFIs from this vaccine, research has to be done also
n other populations since it both from our study as well as other
tudies has been indicated that for example age might inﬂuence
he AEFI pattern. Secondly, our study monitored the vaccine and its
ffects during three months. In order to be sure that there are no
nforeseen late onset effects, a longer follow up period might be
arranted. Thirdly our cohort size was not large enough to iden-
ify any rare AEFIs. In order to detect new rare signals spontaneous
eporting would probably be a more suitable mean, and a case con-
rol study could verify that signal. Cohort studies are inefﬁcient in
nding these types of reactions because you need to follow a very
arge cohort in order to identify these kind of events for example
asesofGuillainBarre syndrome. InEurope theVAESCOconsortium9 (2011) 1941–1947
initiated a study to look at the association between the pandemic
inﬂuenza vaccines using a case control approach [23].
Funding
This study was funded by the Ministry of Health, Welfare and
Sports in the Netherlands.
Ethical approval
Noethical approvalwasnecessary inorder to conduct this study.
Conﬂict of interest: All the authors declare that they do not haveNo, I have not recovered
14. If yes, when did you recover?
15. Which action did you undertake when experiencing the AEFI?
I have discussed the AEFI with a doctor but have not yet received treatment
I have been treated by the doctor
I have not undertaken any of the actions above.
L. Härmark et al. / Vaccine 2
Questions asked in the questionnaires.
16. Did you experience similar complaints by seasonal ﬂu vaccination?
Yes
No
17. Are there other explanations for the reactions, if yes, which ones
18. Have you experienced any other AEFIs?
No, end of questionnaire
19. If yes, have you had any of the below described, frequently occurring AEFI?
Yes
No, skip to question 21






Sweating, chills and inﬂuenza like illness
Lymphadenopathy
Repetition of questions 10–17
21. Have you experienced any other AEFIs?















2009;361(25):2424–35.22. Yes, free text ﬁeld to write the AEFI. For each AEFI reported questions 10–17
were repeated.
Question 21 and 22 was repeated until the patient had ﬁlled in all the
experienced AEFIs.
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